5/28
07:32 am
ctmx
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $3.50 price target on the stock, up previously from $2.25.
Medium
Report
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $3.50 price target on the stock, up previously from $2.25.
5/22
04:17 pm
ctmx
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference [Yahoo! Finance]
Neutral
Report
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference [Yahoo! Finance]
5/22
04:05 pm
ctmx
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
Low
Report
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
5/16
04:25 pm
ctmx
CytomX Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]
Medium
Report
CytomX Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]
5/16
04:15 pm
ctmx
CytomX Therapeutics Announces New Employment Inducement Grants
Medium
Report
CytomX Therapeutics Announces New Employment Inducement Grants
5/11
12:15 am
ctmx
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
5/9
04:35 pm
ctmx
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/9
11:09 am
ctmx
CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its price target raised by analysts at BMO Capital Markets from $3.25 to $3.59. They now have a "market perform" rating on the stock.
High
Report
CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its price target raised by analysts at BMO Capital Markets from $3.25 to $3.59. They now have a "market perform" rating on the stock.
5/9
10:11 am
ctmx
CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
High
Report
CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
5/9
07:21 am
ctmx
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $8.00 price target on the stock.
High
Report
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $8.00 price target on the stock.
5/8
04:23 pm
ctmx
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/8
04:23 pm
ctmx
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager) [Yahoo! Finance]
High
Report
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager) [Yahoo! Finance]
5/8
04:10 pm
ctmx
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
High
Report
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
5/8
04:10 pm
ctmx
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
High
Report
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
5/7
04:27 pm
ctmx
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab) [Yahoo! Finance]
Low
Report
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab) [Yahoo! Finance]
5/7
04:15 pm
ctmx
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
Low
Report
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
5/6
08:04 am
ctmx
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock, up previously from $2.50.
Medium
Report
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock, up previously from $2.50.
5/2
04:04 pm
ctmx
CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling [Seeking Alpha]
Low
Report
CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling [Seeking Alpha]
5/2
09:39 am
ctmx
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains? [Yahoo! Finance]
Medium
Report
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains? [Yahoo! Finance]
5/1
12:34 pm
ctmx
CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its "market perform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $3.25 price target on the stock.
High
Report
CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its "market perform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $3.25 price target on the stock.
5/1
08:00 am
ctmx
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
High
Report
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
4/25
06:54 pm
ctmx
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town [Seeking Alpha]
Low
Report
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town [Seeking Alpha]
4/25
11:01 am
ctmx
Here's Why We're Not Too Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation [Yahoo! Finance]
Neutral
Report
Here's Why We're Not Too Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation [Yahoo! Finance]
4/23
11:04 pm
ctmx
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
4/22
08:03 am
ctmx
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating.
Low
Report
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating.